S
Sino-Biocan
Focuses on the research and development of domestic tools in the field of cell and gene therapy
About Sino-Biocan
Sino-Biocan (Shanghai) Biotech Ltd. operates as a provider of comprehensive solutions for cell preparation tools within the cell and gene therapy (CGT) sector. Founded by Wei Dongbing (also known as Shirley Wei), the company was established to address the reliance on foreign-made cell preparation tools in the Chinese market. Wei brings extensive experience to the firm, having spent over a decade at a Fortune 500 medical device company and later serving as the head of Miltenyi Biotec in China for eight years, which provided her with deep insights into the CGT industry's development and needs.
The company's business model is centered on providing an integrated suite of products and services that cover the entire cell preparation workflow. This includes the development, manufacturing, and sale of intelligent automated equipment, single-use GMP-grade consumables, and liquid reagents. Sino-Biocan serves a clientele that includes biopharmaceutical companies developing cell and gene drugs, contract development and manufacturing organizations (CDMOs), stem cell preparation and application facilities, and cord blood banks. Revenue is generated through the sale of its products and by offering customized technical services and solutions tailored to specific client pipelines.
Sino-Biocan offers a family of products designed to automate and standardize the cell preparation process, including cell separation, culture, washing, concentration, filling, cryopreservation, and recovery. Key product lines include the WUKONG Automated, Closed, Integrated Cell Processing System, the CELL-VOR series for cell separation and concentration, and the CELL-WAV series for cell expansion. These systems are designed to be modular, allowing for flexible and scalable solutions to meet the varying demands of research and commercial production. The company has secured significant funding to support its growth, including an angel round from Sinovation Ventures, a Series A round of nearly RMB 100 million, and a Series B round of a similar amount in March 2024, with investors like Daotong Investment, Sinovation Ventures, and Grand Flight Investment participating.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2024 | $14M | $55M | Yuanyi Investment · Sinovation Ventures | ↗ |
| SERIES AEquity / VC | Jul 2022 | — | — | Neovision Capital | ↗ |
Growth signals
Latest recorded traffic for Sino-Biocan is 90 monthly website visits, down 74.3% over the last three months. Sino-Biocan's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sino-Biocan in the Huangpu ecosystem
The Sino-Biocan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- NCNeovision Capital
- YIYuanyi Investment
Sinovation Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sino-Biocan on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sino-Biocan’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









